Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03936361 · ClinicalTrials.gov registry record · Phase 3

Statins In Intracerbral Hemorrhage

A Phase 3 study of Intracerebral Hemorrhage, sponsored by Beth Israel Deaconess Medical Center.

Recruiting
Registry status
Phase 3
Development phase
1,456
Enrollment target
1
Study location

NCT03936361: Recruiting Phase 3 study of Intracerebral Hemorrhage, sponsored by Beth Israel Deaconess Medical Center.

NCT03936361 is a Phase 3 study of Intracerebral Hemorrhage that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 1,456 participants, above the 1,059-participant average among 31 other Intracerebral Hemorrhage trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03936361, a Phase 3 study of Intracerebral Hemorrhage, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.

RECRUITING
Registry status
Phase 3
Development phase
1,456 participants
Enrollment target
1
Study location

Study Summary

The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype. An MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cerebral small vessel disease, and whether the presence/burden of hemorrhagic markers (i.e. cerebral microbleeds and/or cortical superficial siderosis) on baseline MRI influences the risk of ICH recurrence on/off statin therapy.

Conditions Studied

Interventions

  • DRUG Statins

Study Locations (1)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 1,456 participants
Start Date 2020-06-10
Est. Completion 2028-12-31
Phase Phase 3

What NCT03936361 shows while recruiting

NCT03936361 is an interventional study that assigns participants to a tested intervention. Its 1,456 participants enrollment target places it among the larger protocols in the corpus, above the 1,059-participant average among 31 other Intracerebral Hemorrhage trials with a reported enrollment target (37% higher).

The record links to 1 condition, with Intracerebral Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Statins is the first listed.

NCT03936361 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03936361 about?

NCT03936361 is a clinical study titled "Statins In Intracerbral Hemorrhage". The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype. ...

What is the current status of trial NCT03936361?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,456 participants. The study started on 2020-06-10. Estimated completion is 2028-12-31.

What conditions does trial NCT03936361 study?

This clinical trial studies the following conditions: Intracerebral Hemorrhage.

What interventions are being tested in trial NCT03936361?

The interventions under investigation include: Statins (DRUG).

Who is sponsoring clinical trial NCT03936361?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03936361 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intracerebral Hemorrhage

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03936361's enrollment target sits among peer trials

1,456 6th of 31 higher than 26 of 31 other Intracerebral Hemorrhage trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Intracerebral Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06782347 · 1,454 participants · NA

    Activating SilverSneakers Benefits for Seniors With Osteoarthritis

  • NCT04566328 · 1,450 participants · Phase 3

    Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • NCT05229341 · 1,450 participants · NA

    Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

  • NCT05910268 · 1,450 participants · NA

    Peru Decentralized HIV Care

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03936361, the US trial registry maintained by the National Library of Medicine. NCT03936361 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.